- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07946575
A Study of the Potential Pharmacokinetic Interaction Between Quinidine Sulfate and Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
November 12, 2026 updated by: Trevi Therapeutics
A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study to Evaluate the Effect of Multiple Doses of Quinidine Sulfate, a P-glycoprotein (P-gp) Inhibitor, on the Pharmacokinetics of Nalbuphine Extended-Release Tablets in Healthy Adult Subjects
The primary purpose of this study is to evaluate the effect of quinidine sulfate on the pharmacokinetics (PK) of NAL ER in healthy participants.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Aryany Sanchez
- Phone Number: 203-304-2499
- Email: aryany.sanchez@trevitx.com
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33172
- Recruiting
- Clinical Pharmacology of Miami, LLC
-
Contact:
- Veronica Gomez, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kilogram per meter square (kg/m^2) at screening.
- Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or electrocardiograms (ECGs), as deemed by the principal investigator (PI) or designee.
Exclusion Criteria:
- History of any diagnosed moderate or severe substance use disorder, other than tobacco use disorder, or a history of or current regular excessive consumption of alcohol.
- Positive urine drug or alcohol results.
- Smoker who has smoked or used nicotine containing products within the last 3 months.
- Clinically significant hypokalemia or hypomagnesemia at the screening visit.
- History of prolonged QT syndrome.
- Abnormal liver tests at screening.
- Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
- Abnormal estimated glomerular filtration rate (eGFR).
Note: Other inclusion/exclusion criteria mentioned in the protocol may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: NAL ER and Quinidine
Participants will receive NAL ER followed by NAL ER co-administered with quinidine. |
Oral tablets
Other Names:
Oral tablets |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum Plasma Concentration (Cmax) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
|
Time to Reach Maximum Observed Concentration (Tmax) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
|
Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUC0-Tlast) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
|
Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
|
Apparent Terminal Rate Constant (λz) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
|
Apparent Terminal Half-Life (t1/2) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
Pre-dose and at multiple timepoints post-dose from Days 1 to 9
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time Frame: Up to Day 19
|
Up to Day 19
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Chief Development Officer, Trevi Therapeutics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 3, 2026
Primary Completion (Estimated)
November 30, 2026
Study Completion (Estimated)
December 1, 2026
Study Registration Dates
First Submitted
November 12, 2026
First Submitted That Met QC Criteria
November 12, 2026
First Posted (Actual)
November 18, 2026
Study Record Updates
Last Update Posted (Actual)
November 18, 2026
Last Update Submitted That Met QC Criteria
November 12, 2026
Last Verified
November 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Alkaloids
- Polycyclic Aromatic Hydrocarbons
- Polycyclic Compounds
- Heterocyclic Compounds, 4 or More Rings
- Quinolines
- Morphinans
- Opiate Alkaloids
- Heterocyclic Compounds, Bridged-Ring
- Phenanthrenes
- Quinuclidines
- Cinchona Alkaloids
- Nalbuphine
- Quinidine
Other Study ID Numbers
- NAL00-110
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.